Shares of Dr Reddy's Laboratories fell 6.5% to Rs 1,261 on the BSE on Thursday after the company said commercial supplies of its semaglutide product will be delayed following a quality-related issue linked to the active pharmaceutical ingredient (API) used in certain batches.
In an exchange filing, the company said certain batches of semaglutide were found to be out of specification due to an issue associated with the API used in the product. It added that an investigation is underway to identify the root cause and that appropriate measures are being taken to ensure product quality.
